Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07491445 · ClinicalTrials.gov registry record · Phase 3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 3 study, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
NCT07491445 is a Phase 3 study that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 900 participants.
The verdict
NCT07491445, a Phase 3 study, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Interventions
- DRUG daraxonrasib
- DRUG nab-paclitaxel
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2029-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07491445
The ClinicalTrials.gov registry entry for NCT07491445 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which daraxonrasib is the first listed.
NCT07491445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07491445 about?
NCT07491445 is a clinical study titled "Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma". The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
What is the current status of trial NCT07491445?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2026-03-09. Estimated completion is 2029-03.
What interventions are being tested in trial NCT07491445?
The interventions under investigation include: daraxonrasib (DRUG), nab-paclitaxel (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT07491445?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.